GBIO stock forecast
Our latest prediction for Generation Bio Co's stock price was made on the Sept. 29, 2021 when the stock price was at 24.29$.
In the short term (2weeks), GBIO's stock price should underperform the market by -2.46%. During that period the price should oscillate between -11.63% and +10.19%.
In the medium term (3months), GBIO's stock price should underperform the market by -2.73%. During that period the price should oscillate between -39.49% and +27.83%.Get email alerts
Create a solid portfolio with GBIO
About Generation Bio Co
Generation Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company's non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed. The ctLNP is engineered to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The company's efficient, scalable manufacturing process supports Generation Bio's mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a profit of 0.14$ per share.
The book value per share is 4.75$
Three months stock forecastSept. 29, 2021
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|